Valuation: SANA AB

Market Cap 134.03Cr 13Cr 12Cr 11Cr 10Cr 19Cr 1.29TCr 19Cr 52Cr 659.28Cr 51Cr 49Cr 2.12TCr P/E 2026 *
-
P/E 2027 * -
Enterprise Value 134.03Cr 13Cr 12Cr 11Cr 10Cr 19Cr 1.29TCr 19Cr 52Cr 659.28Cr 51Cr 49Cr 2.12TCr EV / Sales 2026 *
13x
EV / Sales 2027 * 6.41x
Free-Float
90.64%
Yield 2026 *
-
Yield 2027 * -
1 day-2.13%
1 week-0.99%
Current month-17.35%
1 month-18.56%
3 months-26.88%
6 months-37.22%
Current year-55.40%
1 week 9.45
Extreme 9.45
10.34
1 month 9.45
Extreme 9.45
12.11
Current year 9.45
Extreme 9.45
28.3
1 year 9.45
Extreme 9.45
28.3
3 years 1.74
Extreme 1.736
28.3
5 years 1.57
Extreme 1.572
28.3
10 years 1.57
Extreme 1.572
55
Manager TitleAgeSince
Chief Operating Officer 54 01/03/2025
Chief Executive Officer 66 30/04/2022
Chief Tech/Sci/R&D Officer 68 01/01/2014
Director TitleAgeSince
Chairman 71 30/04/2022
Director/Board Member 68 01/01/2015
Director/Board Member 46 19/01/2018
Date Insider Type Main position Quantity % Market Cap. Importance
09/09/26 Buy

Chairman

50,000 0.0362%
01/09/26 Buy

Founder

9,000 0.0065%
28/08/26 Buy

Chief Financial Officer

5,000 0.0036%
Change 5-day change 1-year change 3-year change Capi.($)
-2.63%-0.99%-20.94%+55.51% 14Cr
-0.37%+1.12%+57.21%+84.56% 7.23TCr
-0.07%-2.70%+38.19%+86.90% 6.02TCr
+0.75%+6.06%+36.71%+19.87% 2.77TCr
+0.38%-2.27%-16.52%+359.06% 2.57TCr
+0.50%+1.44%+1.34%-2.57% 2.47TCr
+1.10%+1.86%+25.66%-7.59% 2.07TCr
-1.70%-2.12%+150.24%+323.16% 1.51TCr
+0.13%+2.41%+44.44%+161.72% 1.44TCr
-2.53%-1.39%-6.38%+469.36% 1.42TCr
Average -0.41%-0.41%+30.99%+155.00% 2.75TCr
Weighted average by Cap. -0.11%-1.05%+37.79%+126.41%

Financials

2026 *2027 *
Net sales 10Cr 1.04Cr 91.06L 86.11L 78.1L 1.47Cr 99Cr 1.48Cr 3.98Cr 51Cr 3.89Cr 3.8Cr 162.97Cr 21Cr 2.1Cr 1.85Cr 1.75Cr 1.58Cr 2.98Cr 201.66Cr 2.99Cr 8.08Cr 102.9Cr 7.89Cr 7.72Cr 330.68Cr
Net income - -
Net Debt - -
Logo SANA AB
Saniona AB is a Sweden-based company active in the field of biotechnology. It operates in the area of drugs targeting ion channels to develop therapeutics for pain, central nervous system, and inflammatory or autoimmune diseases. The Company develops a technology platform which enables investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors and potassium channels. The clinical pipeline includes: AN788, a clinical candidate for second line treatment of major depressive disorder (MDD); AN761, to be developed for cognition deficits in schizophrenia and Alzheimer's disease; AN363, a candidate for treatment of pain disorders; and AN346, an anti-inflammatory treatment in inflammatory bowel disease (IBD); as well as several other projects. The Company is engaged in partnerships with Janssen Pharmaceuticals Inc, Pfizer Inc and Atlas Venture Inc.
Employees
44
Date Price Change Volume
28/26/28 SEK 9.455 -2.63% 3,81,393
25/26/25 SEK 9.710 -1.12% 3,79,612
24/26/24 SEK 9.820 -0.81% 3,87,361
23/26/23 SEK 9.900 -1.69% 2,59,760
22/26/22 SEK 10.07 +5.45% 4,43,585

Net sales - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SANION Stock